A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.

What Are The Drugs Involved

The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.

The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.

These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.

What Could This Mean For Bowel Cancer Treatment In The Future

The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.

All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.

Eli Lilly is rapidly expanding its presence in the global obesity treatment market. Its oral weight-loss drug Foundayo has received approval in China, becoming the first GLP-1 pill to get approved in the country.

In another development, its experimental drug combination of eloralintide and tirzepatide recently reported substantial weight loss in an early-stage clinical trial.

The developments come as pharmaceutical companies compete to develop more convenient treatments for obesity, including oral alternatives to injections and dual and triple-acting medicines.

Foundayo Weight Loss Pill Gets Approval In China

Also read: World Diabetes Day: Why Some Diabetes Patients May Not Be Suitable For GLP-1 Treatment, Experts Explain

RecnChina approved orforglipron, marketed as Foundayo in the US, making it the first GLP-1 medication in pill form approved for weight management in the country. Until now, Chinese regulators had authorised GLP-1 medicines for obesity treatment only as injections.

The approval gives Lilly an early advantage over its rival Novo Nordisk, which has also applied to market its oral Wegovy treatment in China.

Foundayo contains orforglipron, an oral, small-molecule GLP-1 receptor agonist. GLP-1 medicines mimic the action of a naturally occurring gut hormone involved in appetite regulation and blood sugar control.

Unlike injectables like Wegovy and Zepbound, Foundayo is taken once daily as a tablet. It can also be taken without restrictions on food and water intake, which may make it a more convenient option for people who prefer not to use injections.

In separate clinical trials, Foundayo produced an average weight reduction of approximately 11% over 72 weeks, while oral Wegovy achieved around 14% over 64 weeks. These results come from different studies.

Experimental Combination EloraTZP Shows Up To 23.3% Weight Loss

Also read: Stopping Mounjaro & Zepbound May Trigger Hallucinations, Mania & Other Psychiatric Symptoms

In another development announced on November 14, Lilly reported promising Phase 2 results for EloraTZP, an experimental combination of eloralintide and tirzepatide.

The combination brings together two medicines that act on appetite and metabolism differently. Tirzepatide, the active ingredient in Zepbound, activates GIP and GLP-1 receptors. Eloralintide is an investigational drug that acts on amylin receptors, which are involved in regulating appetite and feelings of fullness.

In adults with obesity and type 2 diabetes, participants receiving EloraTZP achieved weight loss of up to an average of 23.3% after 48 weeks. Their average starting weight was 232.4 pounds (approximately 105.4 kg). Up to 60% of participants no longer met the BMI criteria for obesity at the end of the study.

The combination also reduced the average blood glucose levels over approximately three months, by up to 2.9 percentage points. Up to 77% of participants achieved normal blood sugar levels, according to Lilly.

However, these are Phase 2 findings reported by Lilly, and the full trial results have not yet been published. Larger studies will be needed to establish the combination's safety and effectiveness in obesity treatment.

More Updates From Lilly

Lilly's latest update included findings from its Phase 3 SURMOUNT-ADOLESCENTS trials, which evaluated Zepbound in adolescents aged 12 to under 18 with obesity.

Participants experienced an average BMI reduction of 21.4% after 72 weeks. More than half no longer met the BMI criteria for obesity. They also reported improvements in aspects of quality of life due to weight reduction, including physical comfort and better body image.

Separately, the company reported Phase 3 findings for retatrutide, an experimental once-weekly medicine that activates three hormone receptors: GIP, GLP-1 and glucagon.

In trials involving adults with obesity, it reduced the severity of obstructive sleep apnoea and knee osteoarthritis pain. Retatrutide, an investigational drug, is not approved for general medical use.

Air pollution in India, especially during winter after Diwali, is one of the alarming environmental and health concerns currently. While we are aware about its adverse effects on lungs and respiratory health, a recent review of five decades of Indian research has suggested its damages may extend to other bodily functions too.

A review of five decades of Indian research has found that more than 91% of epidemiological studies examining the health effects of air pollution reported at least one adverse health effect. These health conditions ranged from cardiovascular and metabolic diseases to pregnancy complications and cancer.

The analysis, conducted by the Centre for Research on Energy and Clean Air (CREA), examined 184 peer reviewed epidemiological studies published between 1975 and 2025.

Out of these, 169 reported at least one positive link between air pollution and an adverse health effect. The findings cement evidence linking polluted air to a wider range of health problems.

What Did The Analysis Report?

Also read: World Diabetes Day 2026: Is India's Toxic Air Adding To Its Diabetes Crisis? What Experts Say

Respiratory diseases were the most frequently investigated health outcomes, featuring in 86 of the 184 studies. Sixteen studies examined mortality, while 11 focused on cardiovascular diseases.

Other research investigated connections between air pollution and diabetes, pregnancy complications, low birth weight, impaired child growth, cancers and other neoplasms, blood disorders, neurological and mental health conditions, metabolic disorders, sleep problems, eye diseases and chronic kidney and bone conditions.

The review also found that the evidence was not limited to privately funded or independent research. Of the 46 government-funded studies included, 44 reported increased health risks.

Similarly, 77 of the 81 studies affiliated with government institutions reported adverse health associations. These institutions included the Indian Council of Medical Research (ICMR), All India Institute of Medical Sciences (AIIMS), the Central Pollution Control Board (CPCB) and the Ministry of Health and Family Welfare.

The 91.8% figure represents the proportion of studies that reported at least one positive association with a health outcome.

Indian Air Pollution Crisis

Delhi accounted for the highest number of studies i.e. 26, followed by Punjab with 13, and Maharashtra and Uttar Pradesh with 11 each. However, the review also highlighted a wide gap in research outside urban centres.

Only 40 studies examined rural populations. Of these, 38 reported at least one adverse health effect linked with air pollution exposure.

The studies accounted for several sources of exposure, including outdoor pollution, household cooking and heating fuels, indoor environments like homes and workplaces, and occupational exposure.

Also read: Delhi Air Pollution: Are Online Classes And Indoor Time Adding To Children's Anxiety?

Polluted Air Can Affect Heart And Metabolism

Fine particulate matter, like PM2.5, can travel deep into the lungs and enter the bloodstream. It can cause inflammation and oxidative stress, processes that may affect blood vessels, metabolic regulation and other organs.

Indian research has also examined the relationship between PM2.5 exposure and type 2 diabetes. A study involving 12,064 adults in Delhi and Chennai, published in BMJ Open Diabetes Research & Care in 2023, found that higher long-term PM2.5 exposure was associated with increased fasting blood glucose, HbA1c and the risk of developing type 2 diabetes. The findings were observational and do not establish that pollution alone caused diabetes.

Air pollution has also been associated with cardiovascular conditions, including hypertension, ischaemic heart disease and stroke. Meanwhile, the CREA review included studies examining neoplasms, a category that includes cancers. However, the review does not establish that 91% of studies independently linked pollution to diabetes, heart disease and cancer. These were among several health outcomes investigated.

India Needs A Better Clean-Air Strategy

The review suggests that air pollution policies need to address the wider picture. Studies examined particulate matter, including PM2.5 and PM10, as well as nitrogen dioxide, sulphur dioxide, ozone, carbon monoxide, black carbon and heavy metals.

CREA has called for stronger air-quality standards, better pollution monitoring, stricter emission limits for industries and power plants, and measures to reduce indoor pollution from solid fuels. It has also emphasised the need to include rural populations in the next phase of India's National Clean Air Programme.

Russia has reported a milestone in its experimental personalised cancer vaccine development. The first patient to complete treatment with the country's mRNA-based cancer vaccine is reportedly doing well as the follow-up scans showed no new tumour growth in the four months after completing therapy.

The update was shared by Alexander Gintsburg, scientific director of Moscow's Gamaleya Research Institute of Epidemiology and Microbiology.

According to a report published by Kursiv, the patient is undergoing monthly examinations at Russia's National Medical Research Centre for Radiology, including high-resolution CT scans. Doctors are paying attention to the lymph nodes where cancer is most likely to spread.

The patient will remain under medical observation for the next three years. While the early findings are promising, they are based on a single patient's experience, which is a major limitation.

Russia's Personalised mRNA Cancer Vaccine

Also read: How The Conditions People Live In Can Quietly Shape Our Risk Of Cancer

The treatment, known as NeoOncovac, is a personalised cancer vaccine developed with the help of messenger RNA (mRNA) technology.

Unlike preventive vaccines that protect people against infections, therapeutic cancer vaccines are designed to help the immune system recognise and attack existing cancer cells.

The vaccine is customised using the genetic characteristics of an individual's tumour. Researchers analyse tumour samples to identify specific mutations that could help distinguish cancer cells from healthy cells.

The mRNA is then designed to instruct the body to produce these targets related to tumour, prompting the immune system to recognise and attack the cancer cells. It aims to make the immune response more specific to the patient's cancer rather than targeting all cancer cells.

Six Patients Received The Vaccine

Also read: American Cancer Society Revises Prostate Cancer Screening Guidelines: What You Need To Know

According to reports citing Gintsburg, six patients with melanoma have received the personalised vaccine so far. The first has completed the treatment course, while the second is reportedly halfway through a course involving 10 administrations. Four other patients have also begun treatment.

Russian specialists expect to treat around 20 patients at the Herzen Moscow Research Institute of Oncology by the end of 2026. The country's Health Ministry has reportedly allocated funding for the treatment and follow-up of 120 patients during 2026 and 2027.

Even though the findings are promising, they should not be interpreted as evidence of a cancer cure. The current update concerns one patient with melanoma, a type of skin cancer. Although doctors have reported no new tumour growth during the follow-up period, four months is too short to establish whether the response will last or whether the cancer could return.

There are also currently no results from a large controlled clinical trial that could establish the vaccine's effectiveness, long-term safety or survival benefit.

Outcomes across more patients will be essential to determine whether the treatment can consistently produce similar results.

Personalised cancer vaccines are an active area of research internationally. In October 2026, Moderna and Merck reported positive late-stage trial findings for their experimental personalised mRNA melanoma vaccine, used alongside the immunotherapy drug pembrolizumab (Keytruda).

The trial involved more than 1,100 patients and found a reduction in the risk of melanoma recurrence or death compared with Keytruda alone. However, this is a different vaccine and treatment from Russia's NeoOncovac.